Hikma Pharmaceuticals (LON:HIK) Rating Reaffirmed
Equities researchers at AlphaValue now has a GBX 2616 price target on Hikma Pharmaceuticals (LON:HIK). AlphaValue and their recent price target indicates a potential upside of 17.63% from the company’s current stock price. The rating has been announced in a recent research report on 3 December.
From a total of 10 analysts covering Hikma Pharmaceuticals PLC (LON:HIK) stock, 10 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 83% of the ratings are positive. The highest target price is GBX 41.5 while the lowest target price is GBX 31.87. The mean of all analyst targets is GBX 38.04 with a 14.80% above today’s (GBX 2221) stock price. Hikma Pharmaceuticals PLC was the topic of 32 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. J.P. Morgan maintained shares on November 18 with “Overweight” rating. Panmure Gordon maintained shares with “Hold” rating and GBX 2120 target share price in a report from a November 2. AlphaValue maintained HIK stock in a recent report from November 11 with “Buy” rating. Jefferies maintained the rating on November 2. Jefferies has a “Buy” rating and a GBX 2615 price target on shares. Finally, HSBC maintained the stock with “Buy” rating in a report issued on a November 3.
Approximately 35,673 shares of stock traded hands. Hikma Pharmaceuticals Plc (LON:HIK) has risen 11.16% since May 6, 2015 and is uptrending. It has outperformed by 11.45% the S&P500.
Hikma Pharmaceuticals PLC is a pharmaceutical firm engaged the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The company has a market cap of 4.45 billion GBP. The Firm is focused on therapeutic areas, such as oncology, diabetes and cardiovascular and central nervous system . It has 27.32 P/E ratio. The Company’s activities are conducted through three business divisions: Branded, Injectables and Generics.